Improving Overall Response Rate (iORR) in HNSCC, increasing to 38.9% (previously 33% iORR)
- Improving Overall Response Rate (iORR) in HNSCC, increasing to 38.9% (previously 33% iORR)
Progression free survival (PFS) continues to improve in 1st line non-small cell lung cancer (NSCLC) patients, estimated at more than 9 months
SYDNEY, Australia, June 01, 2020 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) announces new interim data from its ongoing Phase II TACTI-002 study.
- This data relates to the cut-off date of 4 May 2020 and shows improving efficacy results.
- Immutep CSO and CMO, Dr Frederic Triebel said: TACTI-002 is generating increasingly promising data from both the NSCLC and HNSCC arms of study, as patients continue to receive efti in combination with KEYTRUDA.
- The improving data in both HNSCC and NSCLC patients supports the use of efti in combination with pembrolizumab as a promising new therapeutic option for patients.